o2h Ventures
Andy Morley is an experienced Chief Scientific Officer at both o2h ventures and o2h group since January 2014, with a focus on project management in drug discovery and medicinal chemistry. In addition, Andy serves as CSO at Opal Oncology Limited since June 2012, developing innovative cancer treatments. Previously, Andy held the position of 3D Fragment Library Project Manager and Medicinal Chemistry Consultant at Andy Morley LTD from September 2011 to December 2013, leading independent projects in medicinal chemistry. A significant tenure at AstraZeneca from August 2000 to September 2011 included roles as Principal Scientist and Team Leader in Medicinal Chemistry. Prior experience includes positions at Aventis and Rhone-Poulenc Rorer, contributing to medicinal chemistry leadership. Academically, Andy obtained a PhD from The University of Salford and completed postdoctoral work at Nagoya University.
This person is not in any teams
o2h Ventures
o2h Ventures is an established fund manager based in the heart of the biotech community in central Cambridge. We are a specialist fund that only invests in biotech therapeutics and the intersection between biotechnology and AI/ML. This fund is pivotal in developing the biotech ecosystem in the o2h Group but also has invested into 28 early-stage biotech companies in Great Britain. We have two specialist tax-efficient funds open for investment - 1. The o2h human health SEIS Fund 2. The o2h human health EIS knowledge-intensive Fund Disclaimer: Please refer to the relevant fund’s full risk warnings contained in their Information Memorandums. Your capital is at risk. Investing in early-stage businesses involves risks, including illiquidity, lack of dividends, loss of investment and dilution, and it should be done only as part of a diversified portfolio. o2h Ventures’ funds are targeted exclusively at sophisticated or high-net-worth investors who understand these risks and make their own investment decisions. Tax relief depends on an individual’s circumstances and may change in the future. In addition, the availability of tax relief depends on the company invested in maintaining its qualifying status. Past performance is not a reliable indicator of future performance. You should not rely on any past performance as a guarantee of future investment performance. o2h Ventures Ltd is a limited company registered in England and Wales under number 11397838 and is authorised and regulated by the Financial Conduct Authority (FRN 812245). The registered office and principal place of business is Hauxton House, Mill Scitech Park, Mill Lane, Hauxton, Cambridge, CB22 5HX, United Kingdom.